Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This page contains information about current funding opportunities with Industry. If you are thinking of applying, please read all terms and conditions and feel free to get in touch with the named Oxford contact to talk more about the opportunity. Opportunities are not vetted at the stage of being included on this page. The page is updated on a monthly basis and is not exhaustive.

EVOX Rare Disease Grant

Call for proposals

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on improving the natural delivery capabilities of exosomes and developing an entirely new class of therapeutics. Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of rare and severe diseases with limited treatment options for patients and their families.

Evox has developed an unparalleled proprietary technology platform, DeliverEXTM, to enable it to modify exosomes, to load drugs into exosomes, and to target the delivery of these exosomes to organs of interest. Exosome-based therapeutics have the potential to address some of the limitations of protein, antibody, and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug modalities. Evox is leading the development within this emerging space and the company is poised to break new ground in the treatment of severe rare genetic disorders using its innovative exosome therapeutics.

We have partnered with Evox to call for proposals that will exploit this innovative technology using novel in vivo or in vitro models. Areas of key strategic importance to Evox are rare diseases of the CNS, liver, eye, lung and muscle and the development of therapeutics to treat them. Exploratory studies in other areas will be considered, and studies that investigate the immunological response to exosome therapeutics may also be in scope.

Projects can be up to two years in duration and up to a value of £150,000. Please note that project teams will be required to provide mid-term and final reports.

Eligibility and how to apply

Applications are invited from Principal Investigators and Postdocs with a letter of support from their Head of Department.

Download an application form


Friday 22 October, 5pm

End October - Panel review meeting

Early November - Decisions to applicants 


Applications must also be accompanied by Departmental costing and should be sent to Paul Whyte

Telephone: 07881008999

Novartis opportunities

Further information working with Novartis (SSO login required)




On this page